There is significant variability in the onset and duration of respiratory syncytial virus activity between US metropolitan areas located within the same region, according to a report published in the Pediatric Infectious Disease Journal by biotechnology company MedImmune and the disease surveillance and health care informatics organization SDI.
For example, in the three-year study using MedImmune's surveillance program, RSV Alert, greater than 73% of all the measured areas revealed at least one week of significant RSV activity outside the traditional American Academy of Pediatrics-defined season for disease activity in their region, which is typically November through March. In addition, the study found that the southern region experienced the longest duration and earliest conclusion of RSV activity, while the Midwest region exhibited the latest season commencement and peak. The report also noted that portions of Florida demonstrated year-round RSV outbreaks.
Furthermore, Las Vegas, Portland and Salt Lake City had longer RSV seasons than other areas in the region. Investigators hypothesized that the expanded season could be due to the large influx of visitors from international tourism and business conventions during peak travel months. Additionally, Ohio, Illinois and Missouri had metropolitan areas that experienced an RSV season that was at least four weeks longer than the average for the region.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze